Also found in: Medical.
HDACHuntington's Disease Advocacy Center (Stanford, CA)
HDACHuman Developmental Anatomy Center (National Museum of Health & Medicine; Washington, DC)
HDACHelen Day Art Center (Stowe, VT)
HDACHistone Deacetylase (biochemistry)
HDACHouse Democracy Assistance Commission (US House of Representatives)
HDACHeavy Duty Air Cylinder
References in periodicals archive ?
HBI-8000 is an orally bioavailable, low-nanomolar inhibitor of cancer-associated HDAC enzymes with favorable pharmacology and safety profiles.
Apparently, these HDAC inhibitors allow the brain to learn something, which it would be incapable of after reaching puberty.
Inhibitors of HDAC classes I and II are being studied as a treatment for cancer and neurodegenerative diseases such as Huntington's and Alzheimer's diseases.
This study provides further support for the relevance of SFN as a dietary HDAC inhibitor and chemopreventive agent by showing that SFN can selectively target BPH1, LnCap and PC3 prostate cells while leaving normal PrEC prostate cells virtually unaffected.
HDAC inhibitors are seen as a therapeutically important class of drugs, but the lack of specificity of the current generation of HDAC inhibitors has resulted in significant and often debilitating side-effects.
HDAC inhibitors can slow abnormal tumour cell growth, cause tumour cell death and correct abnormal cell differentiation in a wide range of cancers.
In addition to SB939, S*BIO's pipeline includes a portfolio of complementary HDAC inhibitors and two novel series of unique spectrum kinase inhibitors applicable for the treatment of both solid and hematological tumors.
We are enthusiastic about the initiation of this trial, which further expands our exploration of our HDAC inhibitor, MGCD0103, in treating cancers," said Patrick J.
Gloucester's lead product is FK228, a novel HDAC inhibitor in Phase 2 studies, which the company acquired from Fujisawa Pharmaceutical Co, Ltd.
In addition, CuraGen has an option to select additional HDAC compounds from TopoTarget for clinical development in oncology and other indications for a take-up fee not to exceed $1 million and up to $30 million in milestone payments based on successful development, regulatory approval, and commercialization of each additional product.
The HDAC section of the new complex binds to chromatin to shut off genes, just like all other HDACs; the challenge lies in uncovering what the BHCllO component does.
Olson of the Fred Hutchinson Cancer Research Center in Seattle says he has been surprised that an HDAC inhibitor could work without damaging cells.